Analyst Research
| Report Title | Price |
|---|---|
|
Trading Report for (NVS). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Novartis AG Names New Chairman-Reuters
Reuters reported that Novartis AG's Chairman Daniel Vasella will step down in February 2013 and has named Joerg Reinhardt, as its new chairman from August 1, 2013.
Latest Developments for Novartis AG
- Novartis AG's Drug Ilaris Approved By FDA To Treat Active Systemic Juvenile Idiopathic Arthritis
- Pfizer Inc, Novartis AG And Abbott Laboratories Weigh Bids For Brazil's Ache Laboratorios Farmaceuticos-Reuters
- UK Cost Body Rejects Novartis AG's Breast Cancer Drug-Reuters
- UK Cost Agency Says No To Novartis AG's Blood Cancer Drug Jakavi-Reuters
Latest Key Developments in Pharmaceuticals
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
- Share this
- Link this
- Digg this
Follow Reuters